Nick Woolf was good for the company despite many here that think contrary. You make the key point as well he could only ever sell what the scientist were giving him. If his presentations banged on about time lines or about data - it was only ever him presenting what the labs had put up there for him to show. I did appreciate that he also had a MA in Chemistry from Oxford to go with the FCAA and whilst he wasn't on the science side of things it still allowed him to get around what was given to him and understand what was to be presented. Still if the company wants to sell itself to investors someone that holds a background similar to Nick Woolf is really where they want to start. He'd been selling bio & pharma for long enough overseas as both biotech analyst and banker with - ABN AMRO, Nomura, Bank Of America. The company wants to sell itself they need to put someone up there to do it but it's also up to them to follow through on the data they are passing along - it's like shooting the messenger otherwise.
PYC Price at posting:
1.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)